Capranico G, Palumbo M, Tinelli S, Mabilia M, Pozzan A, Zunino F
Division of Experimental Oncology B, Istituto Nazionale per lo Studio e la Cura dei Tumori, Milan, Italy.
J Mol Biol. 1994 Jan 28;235(4):1218-30. doi: 10.1006/jmbi.1994.1075.
To gain further knowledge of the molecular features of topoisomerase II inhibitors required for drug-receptor complex formation, we investigated the conformational drug determinants of the sequence specificities of drug-stimulated DNA cleavage by computer-aided molecular modeling techniques. DNA sequence specificities of bisantrene, genistein, piroxantrone and ellipticinium were determined by using simian virus 40 DNA and compared to those of mitoxantrone, 4-demethoxydaunorubicin, VM-26 and mAMSA. DNA cleavage intensity patterns of bisantrene and mAMSA were virtually identical in sequencing gels, although these drugs are of distinct chemical classes. Genistein and ellipticinium showed drug-specific DNA cleavage intensity patterns with no apparent similarity to other drugs or to each other. From 54 to 72 drug-stimulated sites were sequenced, and local base sequence specificities were established by statistical analyses. In complete agreement with mAMSA requirements, bisantrene required an adenine at position +1. Ellipticinium required a thymine and excluded a cytosine at position -1. Genistein was the only drug showing base requirements (thymines) at both positions -1 and +1. Piroxantrone (structurally related to mitoxantrone) required a pyrimidine at position -1. Since the common sequence specificity of bisantrene and mAMSA could not be simply explained by the nature of some chemical substituents, a comparative molecular modeling analysis of the drugs was carried out based on their steric and electronic attributes. Energy-minimized structures of mAMSA and bisantrene were very similar, since their planar aromatic domains and pendant side-chains overlapped to a very good approximation. In contrast, their most stable conformations were different from other drug structures. In particular, the planar system and pendant sugar moiety of doxorubicin, which also required an adenine but at position -1, was not superimposed to the corresponding moieties of mAMSA and bisantrene even when considering computer-generated conformations with higher energy contents. The most stable conformations of the other drugs studied revealed specific three-dimensional motifs. Therefore, since in a simple model of drug action each spatial region has a single chemical-pharmacological function, these results suggest that bisantrene and mAMSA share common steric and electronic features that may constitute a specific pharmacophore. We suggest that the molecular properties of this pharmacophore may be critical determinant of the +1 position specificity shown by mAMSA and bisantrene.
为了进一步了解形成药物 - 受体复合物所需的拓扑异构酶II抑制剂的分子特征,我们采用计算机辅助分子建模技术研究了药物刺激的DNA切割序列特异性的构象药物决定因素。使用猿猴病毒40 DNA确定了比生群、染料木黄酮、吡罗蒽醌和椭圆玫瑰树碱的DNA序列特异性,并与米托蒽醌、4 - 去甲氧基柔红霉素、VM - 26和mAMSA的序列特异性进行了比较。尽管比生群和mAMSA属于不同的化学类别,但在测序凝胶中它们的DNA切割强度模式几乎相同。染料木黄酮和椭圆玫瑰树碱表现出药物特异性的DNA切割强度模式,与其他药物或彼此之间没有明显相似性。对54至72个药物刺激位点进行了测序,并通过统计分析确定了局部碱基序列特异性。与mAMSA的要求完全一致,比生群在 +1位需要一个腺嘌呤。椭圆玫瑰树碱在 -1位需要一个胸腺嘧啶并排除一个胞嘧啶。染料木黄酮是唯一在 -1和 +1位都显示碱基要求(胸腺嘧啶)的药物。吡罗蒽醌(在结构上与米托蒽醌相关)在 -1位需要一个嘧啶。由于比生群和mAMSA的共同序列特异性不能简单地用某些化学取代基的性质来解释,因此基于它们的空间和电子属性对这些药物进行了比较分子建模分析。mAMSA和比生群的能量最小化结构非常相似,因为它们的平面芳香域和侧链非常近似地重叠。相比之下,它们最稳定的构象与其他药物结构不同。特别是,柔红霉素的平面系统和侧链糖部分,其在 -1位也需要一个腺嘌呤,即使考虑具有更高能量含量的计算机生成构象,也不能与mAMSA和比生群的相应部分叠加。所研究的其他药物的最稳定构象揭示了特定的三维基序。因此,由于在一个简单的药物作用模型中,每个空间区域都具有单一的化学 - 药理功能,这些结果表明比生群和mAMSA共享可能构成特定药效团的共同空间和电子特征。我们认为这个药效团的分子性质可能是mAMSA和比生群所显示的 +1位特异性的关键决定因素。